Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in Cutis Retrieve available abstracts of 18 articles: HTML format

Single Articles

April 2025
1. SEBASTIAO E, Patton E
   Using Superficial Curettage to Diagnose Talon Noir.
   Cutis. 2025;115:133-134.
   PubMed     Abstract available
   
   
   October 2024
2. AHUJA G, Atoba S, Tahmazian S, Khushbakht M, et al
   Pediatric Melanoma Outcomes by Race and Socioeconomic Factors.
   Cutis. 2024;114:110-111.
   PubMed    
   
   
   July 2024
3. WALLACE CE, Tam I, Beveridge MG
   Cyclosporine for Recalcitrant Bullous Pemphigoid Induced by Nivolumab Therapy for Malignant Melanoma.
   Cutis. 2024;114:E21-E23.
   PubMed    
   
   
   May 2024
4. GOLDWASSER JH
   Comment on "Skin Cancer Screening: The Paradox of Melanoma and Improved All-Cause Mortality".
   Cutis. 2024;113:205.
   PubMed    
   
   
   
5. SABLE KA, Korger SA, Xu YG, Bennett DD, et al
   The Clinical Utility of Teledermatology in Triaging and Diagnosing Skin Malignancies: Case Series.
   Cutis. 2024;113:211-213.
   PubMed     Abstract available
   
   
   February 2024
6. NGO BT
   Skin Cancer Screening: The Paradox of Melanoma and Improved All-Cause Mortality.
   Cutis. 2024;113:94-96.
   PubMed    
   
   
   January 2024
7. MANIACI JL, Raghavan SS
   PRAME Expression in Melanocytic Proliferations in Special Sites.
   Cutis. 2024;113:43-47.
   PubMed     Abstract available
   
   
   November 2023
8. WHITE KD, Kerkvliet AM, Jassim AD
   Aberrant Expression of CD56 in Metastatic Malignant Melanoma.
   Cutis. 2023;112:E13-E15.
   PubMed    
   
   
   
9. SHAFI S, Challa B, Parwani AV, Aung TN, et al
   New Therapies in Melanoma: Current Trends, Evolving Paradigms, and Future Perspectives.
   Cutis. 2023;112:E32-E39.
   PubMed     Abstract available
   
   
   September 2023
10. BORMANN JL, Kerkvliet AM
    Granulomatous Dermatitis in a Patient With Cholangiocarcinoma Treated With BRAF and MEK Inhibitors.
    Cutis. 2023;112:E17-E20.
    PubMed    
    
    
    May 2023
11. SULLIVAN DY, Sakamoto GK
    Eruptive Keratoacanthomas After Nivolumab Treatment of Stage III Melanoma.
    Cutis. 2023;111:E13-E15.
    PubMed    
    
    
    
12. ANDERSON JM, Tejani I, Jarmain T, Kellett L, et al
    Artificial Intelligence vs Medical Providers in the Dermoscopic Diagnosis of Melanoma.
    Cutis. 2023;111:254-258.
    PubMed     Abstract available
    
    
    
13. MASSON R, Kwong A, Chen A, Barajas G, et al
    Disparities in Melanoma Demographics, Tumor Stage, and Metastases in Hispanic and Latino Patients: A Retrospective Study.
    Cutis. 2023;111:245-246.
    PubMed    
    
    
    
14. NGO BT
    Gene Expression Profiling for Melanoma Prognosis: Going Beyond What We See With Our Eyes.
    Cutis. 2023;111:222-223.
    PubMed    
    
    
    
15. LOGAN S, Shinohara MM
    Acral Necrosis After PD-L1 Immune Checkpoint Inhibitor Therapy.
    Cutis. 2023;111:E16-E17.
    PubMed    
    
    
    April 2023
16. KIPERS TG, Mullen HEK, Blumetti B
    Acute Onset of Vitiligolike Depigmentation After Nivolumab Therapy for Systemic Melanoma.
    Cutis. 2023;111:E15-E18.
    PubMed    
    
    
    March 2023
17. LY S, Rollins B, Mohr K, Jennings T, et al
    Hair Repigmentation as a Melanoma Warning Sign.
    Cutis. 2023;111:E18-E21.
    PubMed    
    
    
    January 2023
18. SABLE KA, Shields BE
    The Role of Dietary Antioxidants in Melanoma and Nonmelanoma Skin Cancer.
    Cutis. 2023;111:33-48.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.